Literature DB >> 11852739

Improving care of diabetic patients through a collaborative care model.

Neil Grey1, Rose Maljanian, Ilene Staff, Marisol Cruzmarino de Aponte.   

Abstract

The primary aim of this study was to evaluate the effectiveness of a hospital-based diabetes disease management program. Effectiveness was measured in terms of glycemic control and adherence to American Diabetes Association (ADA) standards of care. Patients participating in the Diabetes LifeCare program received diabetes self-management education, medical management by a primary care provider (PCP) supported by an evaluation and recommendations by a Diabetes LifeCare Advanced Practice Registered Nurse (APRN), nutritional counseling and quarterly follow-up appointments through one year. There was a statistically significant decrease in HbA1c from 9.3 to 7.2 to 6.8. During a six-month follow-up period, adherence to ADA standards for annual eye examinations increased from 64% to 82% and from 66% to 85% for foot examinations as part of a physician visit. Significant improvement in glycemic control and adherence to standards of care can be achieved through a comprehensive program of patient education and management that includes collaborative efforts with the patient's primary care provider.

Entities:  

Mesh:

Year:  2002        PMID: 11852739

Source DB:  PubMed          Journal:  Conn Med        ISSN: 0010-6178


  3 in total

1.  Physicians' perceptions of reimbursement as a barrier to comprehensive diabetes care.

Authors:  Alyssa Pozniak; Lois Olinger; Victoria Shier
Journal:  Am Health Drug Benefits       Date:  2010-01

2.  Improving diabetes management: structured clinic program for Canadian primary care.

Authors:  Daren Lin; Shirley Hale; Erle Kirby
Journal:  Can Fam Physician       Date:  2007-01       Impact factor: 3.275

3.  Perceived access to health care and its influence on the prevalence of behavioral risks among urban African Americans.

Authors:  Vickie L Shavers; Sharada Shankar; Anthony J Alberg
Journal:  J Natl Med Assoc       Date:  2002-11       Impact factor: 1.798

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.